Blackstone Inc vs Cassava Sciences Inc — how do they compare? Blackstone Inc trades at $126.79 (market cap $152.15B), while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Blackstone Inc is far larger — about 2889.3× Cassava Sciences Inc's market cap, and Blackstone Inc pays a 3.99% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BX | FLNA | |
|---|---|---|
Market Cap | $152.15B | $52.66M |
Sector | Financials | Health |
52-Week High | $188.68 | $4.64 |
52-Week Low | $102.12 | $1.09 |
Dividend Yield | 3.99% | — |
Enterprise Value | — | -$33.92M |
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.
Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Trailing returns across standard periods
Latest headlines on both assets
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →